tyrphostin ag17

Tyrphostin AG17 is a biochemical that promotes adipocyte apoptosis in vivo and is an effective modulator of adipocyte differentiation and WAT hypertrophy in vitro and in vivo. It is thought to possibly be useful as a pharmacological obesity treatment. It is a tyrosine kinase antagonist that has also been found to inhibit tumor cell growth.

I-OMe-Tyrphostin AG 538 is a specific IGF-1R inhibitor and ATP-competitive inhibitor of PI5P4Kα (IC50: 1 µM).I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and exhibits preferential cytotoxicity to nutrient-deficient PANC1 cells.

Tyrphostin AG 538 is a chalcone compound, an IGF-1 receptor kinase inhibitor (IC₅0 : for 400 nM) that is potent, cell-permeable, reversible, and competitive.

Tyrphostin AG 528 (Tyrphostin B66) is an inhibitor of EGFR (IC50: 4.9 μM) and ErbB2 (IC50: 2.1 μM).

Tyrphostin AG 568 promotes Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity. It also induces K562 to differentiate.

Tyrphostin AG 1112 is a Bcr-Abl kinase blocker. It can activate the terminal differentiation of K562 cells and the purging of Ph+ cells.

Tyrphostin AG 879 (AG 879) effectively inhibits HER2 ErbB2 with an IC50 of 1 μM, demonstrating 100- and 500-fold higher selectivity for ErbB2 over EGFR and PDGFR, respectively.

Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.

Tyrphostin AG-808 is a 15-human lipoxygenase inhibitor.

Tyrphostin A9 (SF 6847) is an Agricultural acaricide, now superseded. Tyrphostin A9 is firstly designed as an EGFR inhibitor